Recently, Reistone Biopharma Company Limited received the Notice of Clinical Trial approved and issued by NMPA, and was approved to carry out the clinical trial of SHR0302 base ointment to be intended for vitiligo.

Shanghai, China/ Chicago, US/July 13, 2020/Reistone Biopharma Company Limited (Reistone Biopharma) recently announced the appointment of Dr. Qais Mekki as Senior Vice President, Head of International Development, US Site Head. He will be based in Chicago

SHANGHAI, June 18, 2020 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company focused on developing novel medicines for autoimmune and inflammatory diseases, today announced dosing of the first patient i